萘哌地尔75mg与坦索罗辛0.2mg对良性前列腺增生膀胱储尿症状疗效比较:前瞻性多机构研究
这项前瞻性随机多中心研究纳入94例已服用坦索罗辛超过8周但OABSS>3分的BPH患者,经1周洗脱期后分为坦索罗辛0.2mg/d组45例与萘哌地尔75mg/d组49例,治疗8周。两组总IPSS、储尿症状评分、OABSS均显著降低,萘哌地尔组夜尿次数显著减少且改善优于坦索罗辛组。
要点
- 坦索罗辛组与萘哌地尔组总IPSS分别从19.1降至15.1和16.9降至13.1(均P=.001)。
- 萘哌地尔组夜尿次数从2.5降至1.9(P=.001),改善优于坦索罗辛组。
- 两组储尿症状评分与OABSS均显著降低。
核心结论
- 萘哌地尔与坦索罗辛均显著降低总IPSS、储尿症状评分、夜尿次数和OABSS,且萘哌地尔组夜尿改善优于坦索罗辛组。
研究设计与样本
- 前瞻性随机多中心研究,在10个中心开展,共94例患者入组。
- 患者已服用坦索罗辛超过8周且OABSS大于3分,经1周洗脱期后分为坦索罗辛0.2mg每日组45例与萘哌地尔75mg每日组49例,治疗8周。
主要发现
- 坦索罗辛组平均总IPSS从19.1降至15.1(P=.001),萘哌地尔组从16.9降至13.1(P=.001)。
- 坦索罗辛组平均储尿症状评分从8.0降至6.6(P=.002),萘哌地尔组从7.6降至6.1(P=.001)。
- 萘哌地尔组平均夜尿次数从2.5降至1.9(P=.001)。
- 坦索罗辛组平均OABSS从7.7降至6.0(P=.001),萘哌地尔组从7.4降至6.0(P=.001)。
- 两组基线特征无显著差异,坦索罗辛组和萘哌地尔组平均年龄分别为64.8岁和66.0岁。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacies of naftopidil and tamsulosin in terms of reducing storage symptoms in patients with benign prostatic hyperplasia. MATERIALS AND METHODS: This prospective randomized study was performed at 10 centers. Ninety-four patients that had been taking tamsulosin for more than 8 weeks, but had an Overactive Bladder Symptom Score (OABSS) of greater than 3 points, were initially enrolled. After a 1-week washout period, patients were divided into 2 groups. Forty-five patients were treated with tamsulosin 0.2 mg daily, and 49 patients were treated with naftopidil 75 mg daily for 8 weeks. Total International Prostate Symptoms Score (IPSS), storage symptom scores, nocturia times, OABSS, maximal flow rates (Qmax), and postvoid residual volumes were checked before and after the 8-week treatment period. RESULTS: Mean patient ages in the tamsulosin and naftopidil groups were 64.8 and 66.0 years, respectively. Baseline characteristics were not significantly different. In the tamsulosin group, mean total IPSS decreased from 19.1 to 15.1 after the 8-week treated period (P = .001), and in the naftopidil group, mean total IPSS decreased from 16.9 to 13.1 (P = .001). Mean storage symptom scores were reduced in the tamsulosin and naftopidil groups from 8.0 to 6.6 (P = .002) and from 7.6 to 6.1 (P = .001), respectively. Mean nocturia times in the naftopidil groups decreased significantly from 2.5 to 1.9 (P = .001), and mean OABSSs were reduced from 7.7 to 6.0 (P = .001) and from 7.4 to 6.0 (P = .001), respectively. CONCLUSION: Total IPSS, storage symptom scores, nocturia times, and OABSS were significantly reduced by naftopidil and tamsulosin. Moreover, the naftopidil group showed better improvements in nocturia than the tamsulosin group.
引用
- Kwon SY, Lee KS, Yoo TK, et al. Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. Urology. 2017. PMID: 28624553. doi:10.1016/j.urology.2017.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。